Cargando…

Publisher Correction: Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2)

Detalles Bibliográficos
Autores principales:	Gisondi, Paolo, Gottlieb, Alice B., Elewski, Boni, Augustin, Matthias, McBride, Sandy, Tsai, Tsen-Fang, de la Loge, Christine, Fierens, Frederik, López Pinto, José M., Tilt, Nicola, Lebwohl, Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Publisher Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264297/ https://www.ncbi.nlm.nih.gov/pubmed/37249751 http://dx.doi.org/10.1007/s13555-023-00934-y

Ejemplares similares

Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2)
por: Gisondi, Paolo, et al.
Publicado: (2022)

Long‐term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3‐year results from two randomized phase III trials (CIMPASI‐1 and CIMPASI‐2)
por: Gordon, K.B., et al.
Publicado: (2020)

Three‐year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial
por: Warren, R. B., et al.
Publicado: (2021)

Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: 52-Week Results
por: Umezawa, Yoshinori, et al.
Publicado: (2021)

Certolizumab pegol for the treatment of patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials
por: Blauvelt, A., et al.
Publicado: (2018)

Patient Satisfaction with CIMZIA(®) (Certolizumab Pegol) AutoClicks(®) in the UK
por: Bailey, Kathryn, et al.
Publicado: (2020)

Long‐term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo‐controlled studies
por: Blauvelt, A., et al.
Publicado: (2020)

Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: Effect of Demographics and Baseline Disease Characteristics on Efficacy
por: Imafuku, Shinichi, et al.
Publicado: (2021)

Certolizumab Pegol in the Treatment of Psoriasis and Psoriatic Arthritis: Preliminary Real-Life Data
por: Dattola, Annunziata, et al.
Publicado: (2017)

Successful Certolizumab Pegol Treatment of Chronic Anterior Uveitis Associated with Psoriasis Vulgaris
por: Yamaguchi, Keiko, et al.
Publicado: (2018)

5. Certolizumab Pegol for RA in pregnancy
por: Thorne, Iona, et al.
Publicado: (2017)

The Potential Benefits of Certolizumab Pegol in Patients with Concurrent Psoriatic Arthritis and Chronic Plaque Psoriasis: A Case Series and Review of the Literature
por: Rutkowski, David, et al.
Publicado: (2019)

Correction to: Certolizumab Pegol in the Treatment of Psoriasis and Psoriatic Arthritis: Preliminary Real-Life Data
por: Dattola, Annunziata, et al.
Publicado: (2017)

A quantitative systems pharmacology model for certolizumab pegol treatment in moderate-to-severe psoriasis
por: Coto-Segura, Pablo, et al.
Publicado: (2023)

Drug Induced Thrombotic Microangiopathy with Certolizumab Pegol
por: Baysal, Mehmet, et al.
Publicado: (2018)

Certolizumab Pegol for the Treatment of Moderate to Severe Plaque Psoriasis: 16-Week Results from a Phase 2/3 Japanese Study
por: Umezawa, Yoshinori, et al.
Publicado: (2021)

Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis: 52-Week Results
por: Okubo, Yukari, et al.
Publicado: (2022)

Active axial spondyloarthritis: potential role of certolizumab pegol
por: Ranatunga, Sriya, et al.
Publicado: (2014)

Long-Term Durability of Certolizumab Pegol in Patients with Rheumatoid Arthritis Over 5 Years: An Analysis of Pooled Clinical Trial Data
por: Bykerk, Vivian P., et al.
Publicado: (2023)

Associations Between Safety of Certolizumab Pegol, Disease Activity, and Patient Characteristics, Including Corticosteroid Use and Body Mass Index
por: Bykerk, Vivian P., et al.
Publicado: (2021)

Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol
por: Barnes, Theresa, et al.
Publicado: (2007)

New biologics in the management of Crohn’s disease: focus on certolizumab pegol
por: Colombo, Elisabetta, et al.
Publicado: (2009)

Patient Adherence and Efficacy of Certolizumab Pegol in the Management of Crohn’s Disease
por: Blonski, Wojciech, et al.
Publicado: (2012)

Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease
por: Wade, Janet R., et al.
Publicado: (2015)

Certolizumab pegol – Tumor necrosis factor inhibitor for refractory uveitis
por: Sharon, Yael, et al.
Publicado: (2020)

Certolizumab pegol treatment for leg ulcers due to rheumatoid vasculitis
por: Meling, Maureen Tania, et al.
Publicado: (2021)

Renal sarcoidosis associated with certolizumab pegol treatment for psoriatic arthritis
por: Hum, Ryan M, et al.
Publicado: (2022)

Certolizumab Pegol Use in the Treatment of Moderate-to-Severe Psoriasis: Real-World Data From Two Canadian Centers
por: Vender, Ronald B., et al.
Publicado: (2022)

Mapping the certolizumab pegol epitope on TNF and comparison with infliximab, adalimumab and etanercept
por: Henry, Alistair I, et al.
Publicado: (2011)

Two Dosing Regimens of Certolizumab Pegol in Patients With Active Rheumatoid Arthritis
por: Furst, D E, et al.
Publicado: (2015)

Impact of Certolizumab Pegol on Patient‐Reported Outcomes in Patients With Axial Spondyloarthritis
por: Sieper, J., et al.
Publicado: (2015)

Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis
por: Tanaka, Yoshiya, et al.
Publicado: (2020)

Multifocal tuberculosis on certolizumab pegol in a patient followed for rheumatoid arthritis
por: Hannech, Emna, et al.
Publicado: (2021)

Successful treatment of dissecting cellulitis with certolizumab pegol in a pregnant patient
por: Almuhanna, Nouf, et al.
Publicado: (2023)

Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review
por: Yang, Kevin, et al.
Publicado: (2020)

Targeting nanomedicines in the treatment of Crohn’s disease: focus on certolizumab pegol (CDP870)
por: Dinesen, Lotte, et al.
Publicado: (2007)

Certolizumab pegol: an evidence-based review of its place in the treatment of Crohn’s disease
por: Cassinotti, Andrea, et al.
Publicado: (2007)

Prefilled certolizumab pegol (Cimzia(®)) syringes for self-use in the treatment of rheumatoid arthritis
por: Rosa, J, et al.
Publicado: (2010)

Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis
por: Rudwaleit, M., et al.
Publicado: (2016)

Certolizumab pegol in a heterogeneous population of patients with moderate-to-severe rheumatoid arthritis
por: Soriano, Enrique R, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_cfi2q8dcoga0h0l28k95j2p8om